Weekly AHB-137 300 mg for 16 weeks achieved HBV DNA <10 IU/mL in 100% and complete response in 68% at end of treatment without concomitant nucleos(t)ide analogues. Baseline HBsAg stratified outcomes, ...
AusperBio has raised $37m in a Series A financing round to propel the clinical development of AHB-1 for chronic hepatitis B (CHB). The funding round was spearheaded by existing investor the ...
SAN FRANCISCO, May 7, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of ...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted oligonucleotide therapies for chronic hepatitis B (CHB) ...
On early morning of December 24th, 2-2 AHB Wild Card Soldiers and families went out to a location near Moran Station, Seongnam to feed the local nationals who are struggling to find day's work during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results